GlaxoSmithKline - one of the world's leading research-based pharmaceutical and health-care companies - is committed to improving the quality of life by enabling people to do more, feel better and live longer.
The company's 3,300 Canadian employees work to discover, develop, manufacture and market innovative medicines and vaccines.
GlaxoSmithKline has been recognized as one of the top 50 companies to work for in Canada for the past five years (annual Globe & Mail/Hewitt Associates survey).
The company's $250 million Canadian headquarters is located in Mississauga, Ontario.
The company maintains divisional headquarters in Mississauga, Oakville and Laval, with regional offices in Halifax, Quebec City, Montreal, Ottawa, Toronto, Calgary and Vancouver.
GlaxoSmithKline maintains three Canadian manufacturing facilities in Mississauga, Ontario and in Ste-Foy and Laval, Quebec.
Distribution centres are located in Moncton, Mississauga and Calgary.
KEY THERAPEUTIC AREAS & MEDICINES
GSK produces medicines for five major disease areas – respiratory illness, diabetes, virus control, infections and central nervous system disorders. GlaxoSmithKline's medicines treat:
In 2006, GlaxoSmithKline invested close to $60 million in clinical trials in Canada, conducting more than 50 trials and enrolling well over 2,000 patients. The Clinical Development Group typically works on more than 35 different chemical compounds varying from phase I to phase IV trials
GlaxoSmithKline maintains three state-of-the-art manufacturing facilities that produce innovative medicines and vaccines for patients in Canada and around the world.
GSK's Mississauga site is a $120 million, 250,000 square foot manufacturing and development facility, located adjacent to the company's headquarters.
More than 75 medicines and 60 million units are produced annually at the Mississauga facility. Approximately 80 per cent of the production is exported to more than 100 markets worldwide.
In 2006, the Mississauga manufacturing facility produced and shipped approximately $2 billion worth of products, representing approximately 25 per cent of total pharmaceutical shipments produced in Canada.
In 2005-2006, the company was awarded 23 new manufacturing mandates, resulting in a capital investment of $55 million in the Mississauga facility and 230 new job opportunities.
GlaxoSmithKline has secured exclusive worldwide production mandates for its facility in Mississauga to manufacture Mepron® suspension, to treat pneumonia common in AIDS patients, and Malarone® tablets, to treat malaria.
The Mississauga site is also the single global production site for a number of oral liquid products.
INNOVATIVE PARTNERSHIPS
PRIISME™, GlaxoSmithKline's community-based chronic disease management program, helps health-care providers support patients suffering from asthma, diabetes and chronic obstructive pulmonary disease (COPD). More than 50 PRIISME™ projects are currently underway across the country, with many new projects being added regularly.
GlaxoSmithKline created Community Asthma Care Centres (CACCs) in partnership with Canadian hospitals in 1994. Operating in more than 50 locations across the country, CACCs help patients better manage their asthma through education. This has resulted in significant cost savings to the health-care system.
In 1998, The GlaxoSmithKline Foundation, in partnership with the Canadian Hospice Palliative Care Association and hospice palliative care organizations across the country, launched Living Lessons®, a national program to raise awareness of and support for hospice palliative care services.
GlaxoSmithKline is a leading contributor to Health Partners International of Canada (HPIC). HPIC is a charitable organization that provides medications, medical supplies and vaccines, donated by Canada's research-based pharmaceutical companies, to developing world countries and disaster areas. Since 1994, GlaxoSmithKline has contributed $21 million in humanitarian product donations.
